BACKGROUND: Atypical Spitz tumors (AST) are rare spitzoid melanocytic proliferations with an uncertain malignant potential. ASTs have overlapping features of both Spitz nevi and spitzoid melanoma, and consequently generate controversy with diagnosis and management. Sentinel lymph node biopsy (SLNB) has been proposed as a possible means to gain additional insight into the true biologic potential of these tumors; however, previous reports on the use of SLNB in ASTs have been limited by small numbers of patients and short durations of follow-up. METHODS: The authors extracted data from their institution's prospective melanoma database, collected between 1994 and 2007, for all patients with ASTs of uncertain biologic potential. They reviewed the clinical features of these patients, including the sentinel lymph node status, and the histological features of the tumors. RESULTS: A total of 67 patients with ASTs were identified, with a median age of 23.7 years. The mean depth was 2.4 mm. Of these, 57 had a SLNB performed, with 27 (47%) having a positive sentinel lymph node. SLNB-positive cases had a significantly lower mean age than SLNB-negative cases (17.9 vs 28.7 years; P = .013); however, no other significant differences were observed. All 27 patients with a positive SLNB were alive and disease free with median follow-up of 43.8 months. One patient who did not receive a SLNB developed recurrent disease with regional and distant metastases. CONCLUSIONS: ASTs do not appear to behave like conventional melanoma. There is a high incidence of microscopic lymph node deposits in SLNBs, but despite this finding, patients have a favorable prognosis. Our findings raise several questions regarding the malignant potential of ASTs, and the role of SLNB in their management. (c) 2008 American Cancer Society.
BACKGROUND: Atypical Spitz tumors (AST) are rare spitzoid melanocytic proliferations with an uncertain malignant potential. ASTs have overlapping features of both Spitz nevi and spitzoid melanoma, and consequently generate controversy with diagnosis and management. Sentinel lymph node biopsy (SLNB) has been proposed as a possible means to gain additional insight into the true biologic potential of these tumors; however, previous reports on the use of SLNB in ASTs have been limited by small numbers of patients and short durations of follow-up. METHODS: The authors extracted data from their institution's prospective melanoma database, collected between 1994 and 2007, for all patients with ASTs of uncertain biologic potential. They reviewed the clinical features of these patients, including the sentinel lymph node status, and the histological features of the tumors. RESULTS: A total of 67 patients with ASTs were identified, with a median age of 23.7 years. The mean depth was 2.4 mm. Of these, 57 had a SLNB performed, with 27 (47%) having a positive sentinel lymph node. SLNB-positive cases had a significantly lower mean age than SLNB-negative cases (17.9 vs 28.7 years; P = .013); however, no other significant differences were observed. All 27 patients with a positive SLNB were alive and disease free with median follow-up of 43.8 months. One patient who did not receive a SLNB developed recurrent disease with regional and distant metastases. CONCLUSIONS: ASTs do not appear to behave like conventional melanoma. There is a high incidence of microscopic lymph node deposits in SLNBs, but despite this finding, patients have a favorable prognosis. Our findings raise several questions regarding the malignant potential of ASTs, and the role of SLNB in their management. (c) 2008 American Cancer Society.
Authors: Lisa A Kottschade; Travis E Grotz; Roxana S Dronca; Diva R Salomao; Jose S Pulido; Nabil Wasif; James W Jakub; Sanjay P Bagaria; Riten Kumar; Judith S Kaur; Shane Y Morita; Steven L Moran; Jesse T Nguyen; Emily C Nguyen; Jennifer L Hand; Lori A Erickson; Jerry D Brewer; Christian L Baum; Robert C Miller; David L Swanson; Val Lowe; Svetomir N Markovic Journal: Am J Clin Oncol Date: 2014-12 Impact factor: 2.339
Authors: Thomas Wiesner; Jie He; Roman Yelensky; Rosaura Esteve-Puig; Thomas Botton; Iwei Yeh; Doron Lipson; Geoff Otto; Kristina Brennan; Rajmohan Murali; Maria Garrido; Vincent A Miller; Jeffrey S Ross; Michael F Berger; Alyssa Sparatta; Gabriele Palmedo; Lorenzo Cerroni; Klaus J Busam; Heinz Kutzner; Maureen T Cronin; Philip J Stephens; Boris C Bastian Journal: Nat Commun Date: 2014 Impact factor: 14.919
Authors: Eric J Stanelle; Klaus J Busam; Barrie S Rich; Emily R Christison-Lagay; Ira J Dunkel; Ashfaq A Marghoob; Allan Halpern; Daniel G Coit; Michael P La Quaglia Journal: J Pediatr Surg Date: 2015-03-14 Impact factor: 2.545
Authors: Nicholas Latchana; Kelly Regan; J Harrison Howard; Jennifer H Aldrink; Mark A Ranalli; Sara B Peters; Xiaoli Zhang; Alejandro Gru; Philip R O Payne; Lorena P Suarez-Kelly; William E Carson Journal: J Surg Res Date: 2016-07-04 Impact factor: 2.192
Authors: Kachiu C Lee; Sue Peacock; Martin A Weinstock; Ge Alice Zhao; Stevan R Knezevich; David E Elder; Raymond L Barnhill; Michael W Piepkorn; Lisa M Reisch; Patricia A Carney; Tracy Onega; Jason P Lott; Joann G Elmore Journal: J Am Acad Dermatol Date: 2016-09-28 Impact factor: 11.527